title: Inhibiting angiogenesis: interview with Dr Jean Plouët. Interview by Emma Quigley.
abstract: Dr Jean Plouët (Centre de Recherche Cardiovasculaire, INSERM U 689/Institut des Vaisseaux et du Sang) was interviewed by Emma Quigley (Commissioning Editor, Expert Opinion) on 20th June 2006. Born in Brittany, France, Dr Jean Plouët received his MD degree from Nantes University in 1977 and his PhD in Molecular Biology from Paris VII University in 1981. His first research topic, under the supervision of Dr Courtois and Dr Barritault was devoted to the purification and the description of the mechanisms of action of eye-derived growth factor, which turned out to be the retinal fibroblast growth factor (FGF)-2. He was appointed as Charge de Recherche by the Centre National de la Recherche Scientifique in 1981. He later conducted his research on the effect of FGF-2 on light transduction and demonstrated the role of opsin phosphorylation on FGF-2 release from retinal discs in Dr Pouliquen's laboratory. From 1987 to 1989, Dr Plouët worked in the Cancer Research Institute at the University of California, San Francisco, in Dr Gospodarowicz's laboratory where he co-discovered vascular endothelial growth factor (VEGF) with Dr Napoleone Ferrara. He established his own group in Toulouse where he worked on the mechanisms of action of VEGF and vascular targeting by anti-idiotypoc antibodies against VEGF and FGF. In 2005, Dr Plouët moved to Paris where he now works mainly on endogenous inhibitors of angiogenesis acting downstream of VEGF.
authors.forename: Jean
authors.initials: J
authors.lastname: Plouët
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A